Form 4: Macrogenics Director O'Brien Reports Stock Transactions

Federica F. O'Brien, a Director at Macrogenics Inc., reported transactions involving common stock, restricted stock units, and stock options.

Summary

• Federica F. O'Brien, a Director at Macrogenics Inc. (MGNX), reported several transactions on May 18, 2026, and May 19, 2026.
• These transactions include the acquisition of 3,750 shares of common stock, the vesting of 3,750 restricted stock units (RSUs), and the acquisition of 22,000 stock options.
• Following these transactions, O'Brien beneficially owns 14,750 shares of common stock directly.
• The RSUs vested on May 18, 2026, one day before the company's 2026 Annual Meeting of Stockholders.
• The stock options have an exercise price of $4.52 and vest in monthly increments over one year from the grant date, with an expiration date of May 19, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports routine insider transactions without indicating significant positive or negative shifts in insider confidence or company performance.

Positives

• Director Federica F. O'Brien acquired 3,750 shares of common stock.
• 3,750 restricted stock units (RSUs) vested, indicating continued equity awards.
• 22,000 stock options were acquired, suggesting potential for future stock ownership and alignment with company performance.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into the holdings and activities of company directors and officers. These reports are crucial for investors seeking to understand insider sentiment and potential shifts in beneficial ownership.

Stakeholder Impact

• Shareholders: Increased transparency into director's equity holdings and potential future share ownership.
• Employees: May reflect the company's ongoing equity compensation practices.
• Management: Standard reporting requirement, no direct impact noted.

Key Dates

Keywords

Form 4, SEC Filing, Macrogenics Inc., MGNX, Federica F. O'Brien, Director, Stock Options, Restricted Stock Units, Common Stock, Beneficial Ownership